IFM Investors Pty Ltd Acquires 6,601 Shares of DexCom, Inc. (NASDAQ:DXCM)

IFM Investors Pty Ltd lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,794 shares of the medical device company's stock after buying an additional 6,601 shares during the quarter. IFM Investors Pty Ltd's holdings in DexCom were worth $5,416,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Norges Bank purchased a new stake in shares of DexCom during the 4th quarter valued at about $385,367,000. Woodline Partners LP purchased a new stake in shares of DexCom during the 4th quarter valued at about $63,338,000. Northern Trust Corp lifted its stake in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after purchasing an additional 753,857 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of DexCom in the 4th quarter worth approximately $41,295,000. Finally, GAMMA Investing LLC lifted its stake in shares of DexCom by 5,951.7% in the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock worth $34,128,000 after purchasing an additional 491,488 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

DXCM traded up $0.59 during trading on Thursday, reaching $85.46. 3,669,573 shares of the company traded hands, compared to its average volume of 4,414,887. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The firm has a fifty day simple moving average of $84.01 and a 200 day simple moving average of $79.93. The company has a market cap of $33.51 billion, a P/E ratio of 63.78, a PEG ratio of 1.79 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the business earned $0.32 earnings per share. The company's quarterly revenue was up 12.5% compared to the same quarter last year. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on DXCM shares. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. The Goldman Sachs Group started coverage on shares of DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Mizuho started coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average price target of $98.50.

Insider Buying and Selling at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.